Canseco JA, Karamian BA, Patel PD, Divi SN, Timmons T, Hallman H, Nachwalter R, Lee JK, Kurd MF, Anderson DG, Rihn JA, Hilibrand AS, Kepler CK, Vaccaro AR, and Schroeder GD
Study Design: This was a retrospective cohort study., Objective: This study evaluates the patient-reported Health Related Quality of Life outcomes and radiographic parameters of patients who underwent a single level transforaminal lumbar interbody fusion with either a polyetheretherketone (PEEK) or titanium interbody cage., Summary of Background Data: Spinal stenosis with instability is a common diagnosis that is often treated with interbody fusion, in particular transforaminal lumbar interbody fusion. Titanium and PEEK interbody cage properties have been extensively studied to understand their effect on fusion rates and subsidence., Materials and Methods: A retrospective cohort study was conducted from a single, high volume, academic hospital. Health Related Quality of Life outcomes were obtained from Outcomes Based Electronic Research Database and electronic medical record chart review. Subsidence was defined as a loss of 2 mm or more in the anterior or posterior disk height. Spinopelvic alignment parameters measured were sacral slope, pelvic tilt, pelvic incidence, lumbar lordosis, segmental lordosis, and pelvic incidence-lumbar lordosis mismatch. Fusion rates were assessed by the Brantigan-Steffee criteria., Results: The study included a total of 137 patients (108 PEEK, 29 titanium). Overall, no significant changes were noted between the 2 groups at 3 month or 1-year follow-up. Perioperatively, patients did report improvement in all outcome parameters within the PEEK and titanium groups. No significant difference was noted in subsidence rate between the 2 groups. Segmental lordosis significantly increased within the PEEK (+4.8 degrees; P<0.001) and titanium (+4.6 degrees; P=0.003) cage groups, however no difference was noted between groups. No significant difference was noted in fusion between the PEEK and titanium cage cohorts (92.6% vs. 86.2%; P=0.36)., Conclusion: Overall, while PEEK and titanium cages exhibit unique biomaterial properties, our study shows that there were no significant differences with respect to patient-reported outcomes or radiographic outcomes between the 2 groups at the 1-year follow-up time point., Level of Evidence: Level III., Competing Interests: D.G.A.: Cervical Spine Research Society, Society for Minimally Invasive Spinal Surgery: Board or committee member; DePuy, A Johnson & Johnson Company: IP royalties; Paid consultant; Integrity Medical: Paid consultant; ISD: Stock or stock Options; K2M: Paid consultant; PST: Stock or stock Options; Thieme: Publishing royalties, financial or material support. J.A.R.: Cervical Spine Research Society: Board or committee member; Globus Medical: Paid consultant; North American Spine Society: Board or committee member; The Spine Journal: Editorial or governing board; XTANT Medical: Stock or stock Options. M.F.K.: Clinical Spine Surgery: Editorial or governing board; Duratap LLC: Stock or stock Options; Innovative Surgical Designs: Research support; ISASS: Board or committee member. A.S.H.: AAOS Board member or committee member; Amedica: IP royalties; Biomet: IP royalties; Paradigm spine: Stock or stock options. C.K.K.: Biomet: Research support; Clinical spine surgery: Editorial or governing board; Medtronic: Research support; Pfizer: Research support; Regeneration; Technologies Inc.: Research support. A.R.V.: Advanced Spinal Intellectual Properties: Stock or stock Options; Aesculap: IP royalties; AO Spine: Board membership; Atlas Spine: IP royalties; Paid consultant; Avaz Surgical: Stock or stock Options; Bonovo Orthopaedics: Stock or stock Options; Clinical Spine Surgery: Editorial or governing board; Computational Biodynamics: Stock or stock Options; Cytonics: Stock or stock Options; DePuy, A Johnson & Johnson Company: Paid consultant; Dimension Orthotics LLC: Stock or stock Options; Electrocore: Stock or stock Options; Elsevier: Publishing royalties, financial or material support; Flagship Surgical: Stock or stock Options; FlowPharma: Stock or stock Options; Franklin Bioscience: Stock or stock Options; Gamma Spine: Stock or stock Options; Gerson Lehrman Group: Paid consultant; Globus Medical: IP royalties; Paid consultant; Stock or stock Options; Guidepoint; Global: Paid consultant; Innovative Surgical Design: Paid consultant; Stock or stock Options; Insight Therapeutics: Stock or stock Options; Jaypee: Publishing royalties, financial or material support; Medtronic: IP royalties; Paid consultant; none: Other financial or material support; Nuvasive: Paid consultant; Stock or stock Options; Orthobullets: Paid consultant; Paradigm Spine: Stock or stock Options; Parvizi Surgical Innovations: Stock or stock Options; Prime Surgeons: Stock or stock Options; Progressive Spinal Technologies: Stock or stock Options; Replication Medica: Stock or stock Options; Spine Journal: Editorial or governing board; Spine Medica: Stock or stock Options; SpineWave: IP royalties; Paid consultant; Spinology: Stock or stock Options; Stout Medical: Paid consultant; Stock or stock Options; Stryker: IP royalties; Paid consultant; Taylor Franics/Hodder & Stoughton: Publishing royalties, financial or material support; Thieme: Publishing royalties, financial or material support; Vertiflex: Stock or stock Options; Sentryx: Board membership. G.D.S.: Advance Medical: Paid consultant; AOSpine: Other financial or material support; Medtronic: Other financial or material support; Medtronic Sofamor Danek: Research support; Stryker: Paid consultant; Wolters Kluwer Health—Lippincott Williams & Wilkins: Editorial or governing board; Zimmer: Paid consultant. J.K.L.: DePuy, A Johnson & Johnson Company: Paid presenter or speaker; Stryker: Paid presenter or speaker. For the remaining authors there are no conflict of interest or other disclosures., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)